Dr. Reddy's Laboratories

Over 250 million people live with viral hepatitis - and many don’t even know it. On #WorldHepatitisDay2025, we asked people a simple question. Their responses revealed a powerful truth: there’s a significant gap in awareness. Awareness is the first step toward prevention. To help bridge this gap, we’re sharing a quick guide on what hepatitis is and how you can protect yourself and others. Join us in spreading the word. Share this post and help others learn the facts. #Hepatitis #WorldHepatitisDay2025 #LetsBreakItDown #HepatitisAwareness #StopTheSpread #EndHepatitis #TestTreatPrevent #KnowTheTransmission #GlobalHealth #LiverHealth #PatientCentricity #GoodHealthCantWait #WeAreDrReddys

Tino Puri: An enduring inspiration It is with great reverence that I reflect on the remarkable life of Tino Puri (Anupam P. Puri) who passed away last Friday. He served on the board of Dr Reddy’s Laboratories for nearly two decades (2002-2019) and held the role of Lead Independent Director for several terms. We benefited immensely from his wisdom, guidance, and leadership.  I met Tino shortly after his retirement from McKinsey & Company, at their New York office, to invite him to join our board. He brought with him global experience, deep wisdom, and a strong ethical compass. I always cherished our interactions. Those who have known Tino would remember his warm smile and gentle demeanour. He spoke kindly to everyone, gave them his full attention, and made them feel special, and brought out the best in them. When the moment called for it, he delivered tough feedback with clarity and care – always measured, always constructive – evoking just the right response and action. He was the embodiment of what one would call a true gentleman. For the board, he was the glue that brought all the directors together. He helped build the right culture, fostered strong relationships, and encouraged candour in our board discussions. For management, he was the voice of reason, insight, sound judgment, and gentle encouragement. For me, Tino was an invaluable mentor – an elder brother I never had – who wanted nothing but the best for me and from me. Tino nurtured and developed many leaders who continue to make a meaningful impact across the world. He led with both intellect and heart – gracefully blending strategic insight with humility and purpose. We were fortunate to have him as a mentor and a source of enduring inspiration. As we remember Tino, we celebrate a life that inspired excellence, built bridges, and left behind a legacy of wisdom and warmth.   With deepest respect, G V Prasad

🎉🤝 SunWay Biotech’s Subsidiary Bora Health Partners with Dr. Reddy's Laboratories Ltd. to Address Unmet Medical Needs in Taiwan🎉 Taiwan, July 22, 2025 – Bora Health, a subsidiary of SunWay Biotech (1271-TWO), has entered a strategic partnership with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd. to distribute four products in Taiwan, covering infections, CNS disorders, and rare diseases. This collaboration strengthens Bora Health’s hospital-facing portfolio and supports Bora Group’s long-term focus on rare diseases and specialty pharmaceuticals. 🗣️ Bobby Sheng, Chairman of SunWay Biotech, said: "We are proud to partner with Dr. Reddy’s to expand access to high-quality generics and rare disease therapies, addressing critical healthcare needs in Taiwan." 🗣️Satheeshkumar Sriharan, Cluster Head, Greater China at Dr. Reddy’s, added: "With Bora Health’s strong market presence and experienced team, this partnership will help deliver essential treatments to patients who need them most." 🔍 Bora Health, part of SunWay Biotech since 2023, distributes prescription drugs, OTC products, health foods, and skincare through hospitals, clinics, pharmacies, and e-commerce platforms in Taiwan. 🔍 About Dr. Reddy’s: A global pharmaceutical company headquartered in Hyderabad, India, Dr. Reddy’s (NYSE: RDY) operates in over 80 countries, offering affordable and innovative medicines under the mission “Good Health Can’t Wait.”

Are you a problem-solver, aspiring leader, or changemaker? The latest edition of Destination Dr. Reddy’s 2.0 – Case Study Challenge & Internship Interview Drive is now LIVE! This initiative invites bright minds from Management, Engineering, and Pharmaceutical Sciences to explore purpose-driven innovation and contribute to shaping the future of healthcare. Participants will have the opportunity to solve real-world business challenges, gain access to internship opportunities, and potentially secure full-time roles at Dr. Reddy’s. The challenge also offers mentorship from industry experts and exciting goodies! This is more than a competition—it’s a gateway to making a meaningful impact. Your journey to a purposeful career begins here. The last date to register is 16th August. Register now at http://bit.ly/40BnAZb #YoungLeadersProgram #EngineeringCareers #PurposeDrivenCareers #InnovationInHealthcare #GoodHealthCantWait #WeAreDrReddys

Today we announced our Q1 FY'26 financial results. For more details click here: https://shorturl.at/fDqeN #Q1FY26FinancialResults #WeAreDrReddys #GoodHealthCantWait

#ExpandingOperations #WeAreDrReddys #GoodHealthCantWait Ramana M V Anupama Rao Singh Preet darshi Patnaik

We, along with our subsidiary, Aurigene Pharmaceutical Services Limited have joined forces with the Global Antibiotic R&D Partnership (GARDP) to expand access to a novel treatment: Zoliflodacin—an investigational first-in-class drug to treat gonorrhoea (a Sexually Transmitted Infection - STI) This oral antibiotic will be made available to patients in Thailand and South Africa through a commercial sublicensing agreement. These countries participated in GARDP-led Phase 3 trials, which demonstrated strong clinical outcomes. Once approved by national regulators, the product will be launched to help combat the growing threat of antimicrobial resistance (AMR). The U.S.FDA has accepted the New Drug Application by Innoviva Specialty Therapeutics and granted priority review, with a decision expected by December 2025. This collaboration reflects our collective commitment to equitable access, while supporting our bold mission to reach 1.5 billion patients by 2030. #DrReddysXGARDP #WeAreDrReddys #GoodHealthCantWait

We are pleased to present our Integrated Annual Report for FY 2024–25, a year that truly exemplified our theme: Strengthening the Core. Building the Future. This year, we reinforced our strategic pillars and accelerated progress across our core business areas, while laying the foundation for long-term sustainable growth.    Click here to read our Integrated Annual Report FY 2024-25 https://shorturl.at/OA7H3   #DrReddysXSustainability #WeAreDrReddys #GoodHealthCantWait

India has emerged as a global vaccine hub, supplying safe and effective vaccines to over 90 countries—trusted and endorsed by the WHO. From eradicating polio to protecting millions during COVID-19, Indian-made vaccines have consistently upheld the highest standards of quality, safety, and innovation. At a time when the world recognizes India as a vaccine capital, it’s important that public trust in science and our institutions remains strong. Let’s continue fostering collaboration between government, medical instituions, and industry to advance evidence-based, life-saving solutions. Public health must stay above politics.